In the 1970s Chinese researcher Zhang TingDong and colleagues advised the abeyant use of the commonly acclimated Chinese anesthetic arsenic trioxide to amusement astute promyelocytic leukemia (APL).Building on his work, analysis both in China and the West eventually led to the development of the biologic Trisenox by PolaRx Biopharmaceuticals, Inc through NDA, which was accustomed for leukemia analysis by the US FDA in 2000 and after marketed and awash by Cell Therapeutics, Inc., afore getting acquired by Cephalon.
Arsenic trioxide, beneath the tradename Trisenox (manufacturer: Cephalon acquired by Teva), is a chemotheraputic abettor accustomed by the US FDA for the analysis of astute promyelocytic leukemia that is above to "first line" agents, namely all-trans retinoic acerbic (ATRA). It has been apparent that arsenic trioxide induces blight beef to abide apoptosis. Due to the baneful attributes of arsenic, this biologic carries cogent risks.
Use as a cytostatic in the analysis of adverse promyelocytic (M3) subtype of astute myeloid leukemia.The aggregate analysis of arsenic trioxide and all-trans retinoic acerbic (ATRA) has been accustomed by the U.S. Food and Biologic Administration (FDA) for analysis of assertive leukemias University of Hong Kong developed a aqueous anatomy of arsenic trioxide that can be administered orally.